Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Alphabet

Aphria

JPMorgan Chase & Co

Alphabet, JPMorgan, Aphria and Tilray were our top stock trades for Wednesday. Now, let's look at the charts to see what's going on.

4 Top Stock Trades for Wednesday: GOOGL, JPM, APHA, TLRY

Tilray (NASDAQ: TLRY) shares are trading higher Tuesday after Democratic Senators indicated they would push a marijuana reform bill. Shares traded higher on Monday as well.

Why Tilray's Stock Is Trading Higher Again Today

Aurora Cannabis

Canopy Growth

Cronos Group

Cannabis stocks were mostly higher Tuesday after three Democratic senators led by Majority Leader Chuck Schumer said they would make reform legislation a key priority in the current Congress, bolstering hopes for an end to federal prohibition.

Cannabis Watch: Cannabis stocks rally after Chuck Schumer leads drive for reforms that will end federal prohibition

The two companies actually fit together quite well. Here's why.

What Investors Need to Know About the Aphria and Tilray Merger

BigCommerce Holdings, Inc.

FuboTV

PetMed Express

ViacomCBS

Watch out if this trend starts to lose steam, but these five short-squeeze stocks could continue to surge higher in 2021. The post 5 Short-Squeeze Stocks with Big Upside appeared first on InvestorPlace.

5 Short-Squeeze Stocks with Big Upside

Corbus Pharmaceuticals Holdings

HEXO Corp

Global X Cannabis ETF

Inside the top performing stocks in the top ETF of January.

Cannabis ETF Tops in January: 5 Stocks That Led the Way

If 2020 was the year when cannabis companies cleaned up their balance sheets and frontrunners separated themselves from the pack, then 2021 will be a year of consolidation, capital influx, and legislative wins, cannabis investors say. Insider asked top investment firms in the US cannabis industry for their predictions for this year. Though their answers varied, many told us they expect that more states will legalize cannabis, companies will strike deals with rivals, and cash will flow back into the industry. Federal cannabis legislation may see further movement as well.

Top cannabis investors share their best 2021 predictions.

Hint: The story doesn't have a happy ending.

How Will the AMC and GameStop Sagas End? Just Ask Tilray

The regulatory approval bolsters the cannabis company's ambitions to be a top player in the category.

Tilray Wins Authorization to Sell Medical Marijuana in Portugal

Arena Pharmaceuticals

FSD Pharma

Innovative Industrial Properties

22nd Century Group

cbdMD Inc

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will develop in the 2021.

8 Pot Stocks in Focus Amid the WallStreetBets Frenzy

Marijuana stocks have been on a tear since the 2020 elections. With legalization possibly on the way, here are four stocks that could soar.

4 Marijuana Stocks Set for Another Big Increase

NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced that it has received the necessary approvals and market authorization in accordance with the Portuguese legislation to offer Tilray medical cannabis products in Portugal from its GMP-certified EU facility in Cantanhede, Portugal. The market authorization was issued by Infarmed, the Portuguese National Authority of Medicines an

Tilray® Receives the First and Only Market Authorization to Offer Medical Cannabis Products in Portugal

AMC Entertainment

GameStop

Inovio Pharmaceuticals

American Airlines

Blink Charging

Nikola

Virgin Galactic

TherapeuticsMD

Workhorse Group

Pessimists have piled into these companies, but that doesn't seem to be fazing millennial investors one bit.

10 Robinhood Stocks With the Highest Short Interest

Tilray's CEO states the obvious: Marijuana legalization is coming, and soon.

Why Tilray, Aphria, and Aurora Cannabis Stocks Are Lighting Up Today

Tilray CEO Brendan Kennedy is confident that Mexico and Canada's positive stance on marijuana will quickly lead to legalization in the U.S in 18-24 months.

Tilray CEO says he expects U.S. federal cannabis legalization within two years

They were chosen as two main suppliers among four marijuana producers.

Aurora Cannabis and Tilray to Supply Experimental French Medical Cannabis Program

While there are some knuckle-whitening formalities to traverse, the political environment has resolved in favor of a pro-cannabis regime now in control of both houses of Congress and the White House. The upshot momentum has already stoked positive results and investor sentiment in the space.

Opportunity Lights Up in Cannabis Stocks (NASDAQ: KERN) (NASDAQ: TLRY) (OTC US: MEDH) (OTC US: GRWG)

Tellurian

TransEnterix

Could there be more gains ahead for these recovering companies?

These 3 "Comeback Kid" Stocks Have Already Doubled in 2021

The recent reverse merger acquisition of Tilray announcement by Aphria provides an intriguing pseudo-arbitrage opportunity. Initial returns from the start imply a 20%+ gap opportunity.

Aphria And Tilray: Option Strategy Enhances Returns And Mitigates Losses

It's good news all around for the marijuana marketers.

Why Canopy Growth, Tilray, and Aphria Stocks All Popped Today

Tilray's products will treat patients with neuropathic pain, epilepsy and multiple sclerosis who aren't getting relief from existing treatments.

Tilray stock soars 10% after company tapped to provide medical cannabis in French study

Tilray (TLRY) stock is heading higher on Tuesday after announcing a deal with France to supply it with medical marijuana. The post TLRY Stock Alert: 7 Things to Know Today About Tilray's Deal With France appeared first on InvestorPlace.

TLRY Stock Alert: 7 Things to Know Today About Tilray's Deal With France

Shares of Tilray Inc. surged 3.6% in premarket trading Tuesday, after the Canada-based cannabis company said it has been selected by France's National Agency for the Safety of Medicines and Health Products (ANSM) to provide medical cannabis products for experimentation. Tilray said it will supply the medical cannabis, starting in the first quarter of 2021, for the duration of the French experiment, which is expected to last for 18 to 24 months.

Tilray's stock surges after being selected to supply cannabis to France's ANSM for experimentation

NANAIMO, British Columbia & PARIS--(BUSINESS WIRE)--Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis production, research, cultivation, and distribution, announced that it has been selected by the French National Agency for the Safety of Medicines and Health Products (ANSM) to supply Good Manufacturing Processes (GMP) certified medical cannabis products for experimentation in France. Tilray will supply GMP-produced medical cannabis products to serve patients in need for the duration of

Tilray® Selected by French National Agency to Supply GMP-Certified Medical Cannabis Products in France

SNDL Inc.

Let's look at four marijuana penny stocks that can deliver multi-fold returns once federal cannabis legalization occurs in the United States. The post 4 Marijuana Penny Stocks for a Blue-Led Government appeared first on InvestorPlace.

4 Marijuana Penny Stocks for a Blue-Led Government

News for Tilray Brands Stock (TLRY)